Coherus Oncology Inc
F:8C5
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Coherus Oncology Inc
F:8C5
|
US |
|
Viel et Compagnie SA
F:VIC
|
FR |
|
Canal+ SA
F:YA3
|
FR |
Intrinsic Value
The intrinsic value of 
Coherus Oncology Inc (8C5) under the Base Case is 1.212 EUR per share.
Compared with the current market price of 0.922 EUR, the stock appears
Undervalued by 24% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Coherus Oncology Does
Coherus BioSciences makes and sells biosimilar medicines and oncology drugs. Biosimilars are highly similar, lower-cost versions of complex biologic drugs made from living cells. Coherus focuses on products used by doctors, hospitals, clinics, and specialty pharmacies, especially in areas like cancer care and immune-related disease.
- Headquarters
- United States of America US
- Employees
- 147
- IPO date
- Nov 6, 2014
Revenue & Expenses Breakdown
Coherus Oncology Inc
Earnings Waterfall
Coherus Oncology Inc
The intrinsic value for Coherus Oncology Inc (8C5) under the Base Case is 1.212 EUR.
Compared with the current market price of 0.922 EUR, the stock appears Undervalued by 24% .